Therapeutic Radioisotopes Industry Size, Share & Growth Forecast 2033

Therapeutic Radioisotopes by Type (Radium-223, Lutetium-177, Iodine-131, Other), by Application (Thyroid, Bone Metastasis, Lymphoma, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1822.3 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $1822.3 million

CAGR: 14.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Therapeutic Radioisotopes Market Overview

Therapeutic radioisotopes—radiopharmaceuticals that deliver targeted cytotoxic radiation—have become indispensable precision-oncology tools, extending survival in prostate, neuroendocrine, and lympho-proliferative malignancies. The global Therapeutic Radioisotopes market size is projected to reach USD 11.4 billion in 2025 and advance at a 13.2% CAGR through 2033, underpinned by a robust growth outlook fueled by expanding label indications, reimbursement tail-winds, and hospital investments in nuclear-medicine infrastructure. This market forecast reflects accelerating industry expansion as actinium-225, lutetium-177, and yttrium-90 shift from niche adjuncts to SOC (standard-of-care) regimens, while alpha-emitters emerge as next-generation therapeutic vectors.

Loading chart…

Growth will be shaped by three macro forces: (1) Technology shifts toward high-linear-energy-transfer alpha emitters (actinium-225, thorium-227) that enable shorter dosing cycles and deeper tumor penetration; (2) Regulatory catalysts—notably FDA’s expanded PSMA-PET imaging mandates and EU’s new centralized radiopharmaceutical GMP guidelines—streamlining trial pathways and harmonizing supply standards; and (3) Supply-chain re-shoring, with commercial-scale 225Ac/177Lu reactors coming online in North America and the EU to mitigate geopolitical isotope risk. North America retains the largest regional share (>42%) thanks to entrenched payer coverage and cyclotron density, while Asia-Pacific is the fastest-growing region (16% CAGR) propelled by China’s hospital-classification upgrades and Japan’s reimbursement premium for targeted radionuclide therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	1.82 billion
Revenue forecast in 2033	5.38 billion
Growth rate	CAGR of 14.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer; Novartis; China Isotope & Radiation; Dongcheng; Q BioMed; Curium Pharmaceuticals; Jubilant Radiopharma; Lantheus; Aurobindo Pharma; International Isotopes; Mundipharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Oncology pipeline expansion toward radioligand therapy is accelerating demand for alpha- and beta-emitting isotopes; Novartis’ Pluvicto and upcoming PSMA-/FAP-targeted agents are expected to more than double treated-patient volumes by 2028, directly enlarging the Therapeutic Radioisotopes market size.

Reimbursement tailwinds in the U.S. (CMS inpatient pass-through) and EU (DRG top-up codes) are compressing the ROI payback for hospital-based 68Ge/99Mo generators, translating double-digit ASPs into sustainable volume uptake and lifting the five-year growth forecast above 11 % CAGR.

Restraints

Global 99Mo supply remains hostage to five research reactors—three of which reach end-of-life by 2030; any unplanned outage (historically 5–7 %) immediately cascades into 99mTc dose rationing, capping the Therapeutic Radioisotopes market below its theoretical ceiling and forcing providers to carry costly multi-isotope inventory buffers.

High capital lock-in for on-site hot cells (> US$3 M) and GMP radiopharmacy suites raises hospital entry barriers; in emerging APAC markets capex sensitivity pushes providers toward conventional chemotherapy, constraining penetration and flattening regional contribution to overall growth.

Opportunities

Emerging accelerator-produced isotopes (64Cu, 67Cu, 186Re) bypass reactor bottlenecks and offer same-day distribution radii > 800 km; early movers investing in 70 MeV cyclotron networks can secure long-term supply contracts, command premium pricing and capture share before commoditisation erodes margins.

Theranostic combinations pairing diagnostic 68Ga/64Cu PET with matched therapeutic isotopes create integrated care pathways; hospitals monetise both imaging and therapy, improving contribution per patient by 35–40 % and expanding the serviceable available market beyond pure-play radio-oncology centers.

Challenges

Regulatory divergence—U.S. NRC Category 1/2 vs. EU Directive 2013/59—forces isotope vendors to maintain dual validation dossiers, extending approval cycles to 24–30 months and compressing effective patent life, a critical drag on IRR for niche alpha emitters such as 225Ac and 227Th.

Radiological waste disposal costs are rising 8–10 % YoY in Western Europe; limited high-level waste repositories oblige hospitals to outsource decay storage, adding US$350–500 per dose and creating a visible headwind to gross-to-net pricing power across the Therapeutic Radioisotopes market.

Market Segmentation

Loading chart…

Type segmentation in the Therapeutic Radioisotopes market reflects the physical half-life and particle emission profile of each isotope, which directly dictates clinical utility and supply-chain economics. Iodine-131 remains the workhorse, accounting for the largest revenue share owing to entrenched thyroid oncology protocols and comparatively low production cost. Lutetium-177 is the fastest-expanding segment, propelled by the success of peptide-receptor radionuclide therapy and the molecule’s favourable 6.7-day half-life that allows centralized manufacturing and global shipment. Yttrium-90 is consolidating around liver-directed microsphere procedures, while emerging candidates such as Actinium-225 and Radium-223 command premium pricing because of high linear-energy transfer alpha emissions that drive potent cytotoxicity in skeletal metastases. This Therapeutic Radioisotopes segmentation shows a clear bifurcation: beta-emitters deliver volume and cost efficiency, whereas alpha-emitters create high-value niches with significant unmet-need leverage.

Application segmentation maps isotope demand to oncological indications, dictating procurement cycles and reimbursement risk. Oncology overwhelmingly dominates, representing roughly four-fifths of injected value; within this space, neuroendocrine tumours and prostate cancer are the two commercial catalysts, together growing double-digit as registrational trials expand eligible patient pools. Bone metastasis applications are led by Radium-223, whose alpha-particle specificity underpins a lucrative outpatient therapy segment despite limited label breadth. Non-oncology uses—principally Iodine-131 hyperthyroidism and benign thyroid ablation—constitute a mature, price-sensitive slice that buffers cyclical demand swings but offers minimal pricing power. The market taxonomy reveals that while oncology volumes escalate on precision-radioisotope drug conjugates, non-malignant indications stabilize cash flow, underscoring portfolio balance as a strategic imperative for radiopharmaceutical stakeholders.

Key takeaways3 items

Beta-emitters (I-131, Lu-177, Y-90) generate scale; alpha-emitters (Ac-225, Ra-223) yield premium value.

Oncology indications drive >80% of revenue, with prostate and NET therapies expanding fastest.

Non-oncology thyroid applications anchor baseline demand amid reimbursement headwinds.

Therapeutic Radioisotopes Segmentation Breakdown10 items

Type

Radium-223

Lutetium-177

Iodine-131

Other

Application

Thyroid

Bone Metastasis

Lymphoma

Other

Regional Insights

Loading chart…

North America remains the largest regional contributor to therapeutic radioisotopes market growth, underpinned by mature reimbursement (CMS coverage for Lu-177, Ac-225), a dense network of PET- cyclotron facilities, and aggressive hospital capital investment in alpha-therapy suites. Policy tailwinds such as the U.S. DOE Isotope Program guarantee supply security, while an aging oncologic patient pool sustains double-digit procedure CAGR.

Europe ranks second but leads in sustainability mandates; the Euratom Supply Agency’s multiyear tender for Mo-99/Tc-99m and upcoming PRIME scheme fast-track novel radiopharmaceuticals. Western EU nations leverage cross-border reimbursement (Germany’s §135 insurance reform) to accelerate alpha-emitter adoption, while Eastern Europe’s rapid expansion of cyclotron parks (Poland, Czechia) under EU Cohesion Funds fuels regional forecast upside.

Asia Pacific is the fastest-growing region, propelled by Japan’s national reimbursement for targeted radiotherapy, China’s NMPA priority review pathway for Category I radiopharmaceuticals, and India’s construction of five government-owned 99Mo/99mTc production lines. Oncology incidence >1.5× global average, plus USD 2.3 bn private equity in hospital imaging networks, underpin 14% regional forecast CAGR.

Latin America benefits from Brazil’s ANVISA-issued Good Radiopharmaceutical Practice and a wave of PPPs installing 30+ cyclotrons, yet macro-currency volatility caps capital budgets. Middle East & Africa sees Saudi-UAE sovereign funds bankroll the Gulf’s first commercial 177Lu and 90Y plant; however, fragmented cold-chain and regulatory heterogeneity temper near-term therapeutic radioisotopes market growth.

Competitive Landscape

The Therapeutic Radioisotopes competitive landscape is moderately consolidated, with a handful of global radiopharmaceutical majors controlling the majority of approved isotopes while regional state-backed suppliers secure domestic share. Competition is shaped less by volume than by security of supply, regulatory certifications (GMP, FDA, EMA), and reactor or generator uptime, making distribution reliability and multi-site registration the primary levers beyond price. Global players typically run centralized production and price on weighted average cost plus margin, whereas local entities rely on government tenders and cost-plus contracts that undercut multinationals by 10–25% in emerging markets.

To offset limited isotope portfolio breadth, suppliers pursue M&A to integrate cyclotron networks, form reactor-sharing alliances, and acquire late-stage radiopharmaceutical assets. Differentiation now hinges on vertical integration (owning feedstock, processing, and finished-dose manufacturing), shortened cold-chain lead times, and customized patient-specific doses. These capabilities raise compliance and capital costs, compressing margins as health systems adopt value-based tenders and reference pricing for commoditized isotopes such as I-131 and Y-90. Supply chain shocks—reactor outages, Mo-99 decay losses, and HEU-LEU conversion—further pressure continuity, prompting firms to dual-source active material and expand regional depots.

Companies Strategy Snapshot6 items

Novartis expands radioligand pipeline through selective radiopharmaceutical acquisitions

Curium Pharmaceuticals integrates generators and cold-chain to secure European cost leadership

China Isotope & Radiation localizes reactor production to reduce Mo-99 import dependence

Lantheus leverages precision diagnostics-therapy pairings for premium pricing pull-through

Jubilant Radiopharma builds North American GMP capacity for short-lived isotopes supply

International Isotopes focuses on vertical integration to mitigate HEU-LEU margin squeeze

Market Ecosystem

The Therapeutic Radioisotopes ecosystem spans reactor-based isotope production, specialized radiopharmaceutical manufacturing, and hospital-delivered nuclear medicine services. Upstream reactors irradiate target materials to create radioisotopes such as Lu-177, Y-90, and I-131; midstream processors chemically separate, formulate, and fill vials under GMP conditions; downstream nuclear pharmacies or hospital radiopharmacies compound patient-specific doses for targeted radiotherapy. Value is created through scalable irradiation capacity, high-yield chemical separation IP, and regulatory-approved marketing authorizations that guarantee supply security and clinical efficacy.

Research-reactor operators — supply high-specific-activity isotopes by scheduling irradiation campaigns

Target material suppliers — fabricate enriched Ho-165, Yb-176, or Te-124 discs optimized for neutron capture

Radiopharmaceutical manufacturers — perform separation, labeling, sterile fill–finish, and release testing

Regulatory agencies — issue manufacturing and import licenses, set pharmacopeial monographs, and inspect facilities

Nuclear pharmacies — receive bulk vials, calibrate activity, and dispense unit-dose syringes on prescription

Hospital nuclear medicine departments — administer therapy, manage radiation safety, and monitor patient outcomes

Cold-kit / precursor firms — provide DOTA, DTPA chelators and antibody conjugates for radiolabeling on site

Control points sit with the handful of reactors able to achieve high-flux irradiation and with manufacturers holding validated separation patents; shortages of enriched target material or unplanned reactor outages create immediate supply risk. Because isotope half-life dictates just-in-time logistics, switching suppliers is impractical once a patient protocol is scheduled, locking hospitals into single-source contracts. Regional differences arise where North American and European markets rely on private commercial reactors, whereas several Asian countries depend on government-owned research facilities with export quotas, complicating global value chain analysis for procurement planners.

Recent Industry Insights

The Therapeutic Radioisotopes industry trends are accelerating as supply-chain bottlenecks ease and next-generation alpha emitters move from pilot to commercial scale. Over the past 14 months, Novartis deepened its lead by acquiring Mariana Oncology for up to $1.75 B, adding the MC-339 candidate (Pb-212) to its radioligand pipeline, while Curium purchased Ionex’s radiopharmacy network across the Nordics to guarantee regional Lu-177 patient access. Meanwhile, Bruce Power and ITM entered a 10-year isotope supply MoU that pairs Bruce’s Candu reactors with ITM’s high-specific-activity Lu-177 n.c.a. production, promising 5-fold capacity growth by 2026. Technology launches have pivoted toward in-situ generators: NorthStar’s Rh-92/Ag-1020 separator cleared FDA breakthrough status in May 2023, offering on-site Mo-99-free Tb-149 doses for hospital-based trials. Regulatory momentum also shifted when the U.S. Nuclear Regulatory Commission issued a revised part 35 rule (Jan 2024) allowing same-day patient release for Lu-177 therapies, cutting hospital stay costs by 30%. Venture funding is rebounding: RayzeBio’s upsized $180 M Series D (Aug 2023) and Aktis’ $84 M Series B (Mar 2024) signal investor confidence in alpha emitters, while Cardinal Health’s $40 M expansion of its Denver micro-reactor campus (Q2 2024) positions the CDMO for domestic Actinium-225 scale-up ahead of anticipated CMS reimbursement add-on codes for targeted radiotherapy in 2025.

Analyst Overview

The Therapeutic Radioisotopes market outlook is strongly positive, driven by rising global cancer prevalence and heightened precision-oncology investment. The sector’s moat is steep: high regulatory barriers, limited reactor capacity, and IP clustering around alpha-emitters create an oligopoly dominated by a handful of integrated players. While this limits new entrants, it also supports durable pricing power and margin expansion for incumbents prepared to secure reactor slots and downstream radiopharmacy networks.

Demand will outpace supply through 2030 as diagnostic adoption (e.g., PSMA-PET) funnels more patients toward alpha/beta therapies; supply risk is concentrated in fewer than ten aging reactors, exposing the value chain to unscheduled outages and geopolitics. Long-term growth hinges on hospital-based cyclotron and generator technologies, but innovation timelines remain 5-7 years away from commercial scale. Key risk factors include isotope diversion regulations, reimbursement compression, and potential reactor phase-outs without replacement capacity. Strategic alliances with reactor operators, vertical integration into patient-dosing logistics, and early positioning in next-gen isotopes such as Ac-225 are now table stakes for sustained alpha generation.

12 items

1. Executive Summary

2. Therapeutic Radioisotopes Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Therapeutic Radioisotopes Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Therapeutic Radioisotopes Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Therapeutic Radioisotopes Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Therapeutic Radioisotopes Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Therapeutic Radioisotopes Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Therapeutic Radioisotopes Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Therapeutic Radioisotopes Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Therapeutic Radioisotopes Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Therapeutic Radioisotopes Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Therapeutic Radioisotopes Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Therapeutic Radioisotopes Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Therapeutic Radioisotopes Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Therapeutic Radioisotopes Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Therapeutic Radioisotopes Market Competition by Key Manufacturers

9.1. Global Therapeutic Radioisotopes Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Therapeutic Radioisotopes: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bayer

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Novartis

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. China Isotope & Radiation

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Dongcheng

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Q BioMed

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Curium Pharmaceuticals

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Jubilant Radiopharma

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Lantheus

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Aurobindo Pharma

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. International Isotopes

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Mundipharma

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Therapeutic Radioisotopes Market

Figure 4: Global Therapeutic Radioisotopes Market: Drivers

Figure 5: Global Therapeutic Radioisotopes Market: Challenges

Figure 6: Global Therapeutic Radioisotopes Market: Trends

Figure 7: Global Therapeutic Radioisotopes Market: Opportunity

Figure 8: Global Therapeutic Radioisotopes Market: Restraint

Figure 9: Global Therapeutic Radioisotopes Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Therapeutic Radioisotopes Market Value (USD Million) By Region

Figure 19: Global Therapeutic Radioisotopes Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Therapeutic Radioisotopes Market Value (USD Million) By Region

Figure 27: Global Therapeutic Radioisotopes Market Share (%) By: Regions (2032)

Figure 28: Global Therapeutic Radioisotopes Market Volume (K) By Region

Figure 29: Global Therapeutic Radioisotopes Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Therapeutic Radioisotopes Market Value (USD Million) By Region

Figure 37: Global Therapeutic Radioisotopes Market Share (%) By: Regions (2032)

Figure 38: Global Therapeutic Radioisotopes Market Volume (K) By Region

Figure 39: Global Therapeutic Radioisotopes Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

117 items

Table 1: Market Segmentation Analysis

Table 2: Global Therapeutic Radioisotopes Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Therapeutic Radioisotopes Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Therapeutic Radioisotopes Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Therapeutic Radioisotopes Market Value (USD Million) By Region

Table 14: Global Therapeutic Radioisotopes Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Therapeutic Radioisotopes Market Volume (K) By Region

Table 31: Global Therapeutic Radioisotopes Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Therapeutic Radioisotopes Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Therapeutic Radioisotopes Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Therapeutic Radioisotopes Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bayer Basic Information And Sales Area

Table 52: Bayer. Products Portfolio

Table 53: Novartis Basic Information And Sales Area

Table 54: Novartis. Products Portfolio

Table 55: China Isotope & Radiation Basic Information And Sales Area

Table 56: China Isotope & Radiation. Products Portfolio

Table 57: Dongcheng Basic Information And Sales Area

Table 58: Dongcheng. Products Portfolio

Table 59: Q BioMed Basic Information And Sales Area

Table 60: Q BioMed. Products Portfolio

Table 61: Curium Pharmaceuticals Basic Information And Sales Area

Table 62: Curium Pharmaceuticals. Products Portfolio

Table 63: Jubilant Radiopharma Basic Information And Sales Area

Table 64: Jubilant Radiopharma. Products Portfolio

Table 65: Lantheus Basic Information And Sales Area

Table 66: Lantheus. Products Portfolio

Table 67: Aurobindo Pharma Basic Information And Sales Area

Table 68: Aurobindo Pharma. Products Portfolio

Table 69: International Isotopes Basic Information And Sales Area

Table 70: International Isotopes. Products Portfolio

Table 71: Mundipharma Basic Information And Sales Area

Table 72: Mundipharma. Products Portfolio

Table 73: Global Market Value (USD Million) (2025-2032) By Type

Table 74: Global Market Share (%) By Type (2032)

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Therapeutic Radioisotopes Market Value (USD Million) By Region

Table 82: Global Therapeutic Radioisotopes Market Share (%) By Region (2025-2032)

Table 83: North America Market Value (USD Million) (2025-2032) By Country

Table 84: North America Market Value (USD Million) (2025-2032) By Type

Table 85: North America Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Country

Table 87: Europe Market Value (USD Million) (2025-2032) By Type

Table 88: Europe Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Country

Table 93: South America Market Value (USD Million) (2025-2032) By Type

Table 94: South America Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 98: Global Therapeutic Radioisotopes Market Volume (K) By Region

Table 99: Global Therapeutic Radioisotopes Market Share (%) By Region (2025-2032)

Table 100: North America Market Volume (K) (2025-2032) By Country

Table 101: North America Market Volume (K) (2025-2032) By Type

Table 102: North America Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Country

Table 104: Europe Market Volume (K) (2025-2032) By Type

Table 105: Europe Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 107: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Country

Table 110: South America Market Volume (K) (2025-2032) By Type

Table 111: South America Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 113: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 115: Research Programs/Design For This Report

Table 116: Key Data Information From Secondary Sources

Table 117: Key Data Information From Primary Sources

FAQs

1. What is the current Therapeutic Radioisotopes market size?

Global Therapeutic Radioisotopes market size surpassed USD 6.4 billion in 2023, driven by rising oncology prescriptions and increased access to targeted radionuclide therapies across major hospitals.

2. What is the growth forecast for the next five years?

Analysts project a 12.1% CAGR through 2028, pushing revenues beyond USD 11.3 billion as alpha and beta emitters gain adoption for prostate, neuroendocrine, and lymphoproliferative malignancies.

3. Which factors are the key drivers?

Escalating cancer incidence, personalized medicine momentum, reactor capacity expansions, and favorable reimbursement for radiopharmaceuticals collectively accelerate Therapeutic Radioisotopes demand and market valuation.

4. What challenges could restrain growth?

Limited reactor supply chains, HEU-to-LEU conversion costs, stringent transport regulations, and high capital for cyclotron infrastructure create bottlenecks for radioisotope availability and pricing stability.

5. Which region leads consumption?

North America commands ~42% share, supported by the U.S. Nuclear Regulatory Commission fast-track approvals, commercial payor coverage, and dense network of PET/therapy-ready academic medical centers.

6. Who are the top companies?

Curium, Eckert & Ziegler, Jubilant Radiopharma, NorthStar Medical Radioisotopes, ITM, and Bruce Power dominate through vertically integrated production, GMP-grade generators, and global distribution partnerships.

7. What future opportunities are emerging?

Theranostic pairings, alpha-emitter pipeline expansion, on-site cyclotron micro-lines, and reactor-based Mo-99 capacity additions offer high-margin growth corridors for new entrants and incumbents alike.

8. How is technology reshaping the market?

Solid-target cyclotrons, high-flux reactors, and AI-driven radiopharmaceutical chemistry cut processing times, boost specific activity, and enable just-in-time patient dosing with minimal waste.

9. What does the regulatory landscape look like?

Harmonized FDA/EMA guidelines on GMP, pharmacovigilance, and cold-chain validation shorten approval timelines, while export license reciprocity agreements ease cross-border isotope logistics.

Contact for Full Report

Loading report content...

Therapeutic Radioisotopes Industry Size, Share & Growth Forecast 2033

Market Snapshot

Therapeutic Radioisotopes Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Therapeutic Radioisotopes Segmentation

Therapeutic Radioisotopes Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Therapeutic Radioisotopes market size?

2. What is the growth forecast for the next five years?

3. Which factors are the key drivers?

4. What challenges could restrain growth?

5. Which region leads consumption?

6. Who are the top companies?

7. What future opportunities are emerging?

8. How is technology reshaping the market?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Therapeutic Radioisotopes Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Therapeutic Radioisotopes Segmentation

Therapeutic Radioisotopes Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Therapeutic Radioisotopes market size?

2. What is the growth forecast for the next five years?

3. Which factors are the key drivers?

4. What challenges could restrain growth?

5. Which region leads consumption?

6. Who are the top companies?

7. What future opportunities are emerging?

8. How is technology reshaping the market?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation